Re: Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

Similar Items

• Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine: For the Prevention of Genital Warts in Males
  od: Garnock-Jones, Karly P., i dr.
  Izdano: (2011)
• Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males: Profile Report
  od: Garnock-Jones, Karly P., i dr.
  Izdano: (2012)
• Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years
  od: Einstein, Mark H, i dr.
  Izdano: (2011)
• Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
  od: Kohli, Michele, i dr.
  Izdano: (2012)
• Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine
  od: Nygård, Mari, i dr.
  Izdano: (2015)